897 High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer

Heidenreich, Axel; Ohlmann, Carsten; Olbert, P.; Hegele, Axel

doi:10.1016/s1359-6349(03)90923-2

Cited by 43 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ibandronate administered on 3 consecutive days (total dose, 18 mg), followed by standard dosing of 6 mg ibandronate every 4 weeks. In a study of 53 patients with urologic malignancies, bone-pain scores were improved in 83% of patients (mean score p < .001 versus baseline on day 3), with 25% of patients becoming pain-free [36]. Mean bone-pain scores remained below baseline for 20 weeks and were accompanied by improved patient functioning.…”

Section: Studies Of Intensive Ibandronate Dosingmentioning

confidence: 99%

Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data

Bell

2005

The Oncologist

View full text Add to dashboard Cite

Bone involvement is a significant complication of metastatic cancer that occurs in up to 95% of multiple myeloma patients, up to 75% of breast and prostate cancer patients, and 15%-40% of patients with primary lung, colon, or kidney tumors [1,2]. Bone metastases cause considerable morbidity, including severe pain, immobility and disability, pathologic fractures, life-threatening hypercalcemia, and spinal cord compression. These problems have a major impact on patient quality of life. The spread of tumor cells to bone normally signifies that the cancer is incurable with, for example, only 20% of breast cancer patients alive at 5 years after the initial diagnosis [1]. The primary treatment goal for metastatic bone disease is therefore to alleviate symptoms and enable patients to continue with a normal life for as long as possible.Bisphosphonates are the standard of care for treating metastatic bone disease. These agents inhibit the function of osteoclasts, which are bone-resorbing cells essential for bone remodeling [3]. The presence of tumor metastasis in bone tissue results in excessive osteoclast activity with consequent destruction of bone architecture and loss of structural integrity. Bisphosphonates have the potential to prevent bone complications, and current recommendations suggest that all

show abstract

Section: Studies Of Intensive Ibandronate Dosingmentioning

confidence: 99%

Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data

Bell

2005

The Oncologist

View full text Add to dashboard Cite

show abstract

“…In the clinical setting, phase II studies showed that intensive ibandronate dosing, 4 mg infused over four consecutive days [37] and 6 mg infused over three consecutive days as a loading dose followed by intermittent dosing every 3-4 weeks [38,39], relieves moderate-to-severe metastatic bone pain without adverse renal effects. Because bisphosphonates cause renal toxicity through their intracellular effects on renal tubular cells, their intracellular potencies and renal tissue kinetics are likely to be important when considering differences among renal safety profiles.…”

Section: Renal Toxicitymentioning

confidence: 99%

Preclinical Perspectives on Bisphosphonate Renal Safety

2005

View full text Add to dashboard Cite

Renal insufficiency is not rare in cancer patients who may receive nephrotoxic medications as antineo-plastic agents or for comorbid conditions. Thus, the choice of a particular bisphosphonate for patients with metastatic bone disease should be based not only on efficacy but also on the risk for renal deterioration. Some i.v. bisphosphonates have been associated with occasional renal toxicity in the clinical setting. Preclinical studies have also shown that there may be considerable differences among bisphosphonate renal safety profiles. Comparative studies show variations in the risk for histopathologic damage and the ability to cause cumulative toxicity during intermittent dosing. Reasons for the differences among bisphosphonates are not fully understood; however, research shows that they may be influenced by pharmacokinetic properties such as renal tissue half-life or protein binding and intracellular potency. Further preclinical analyses are needed to confirm and evaluate differences among bisphosphonates.

show abstract

“…Two, open-label, nonrandomized, prospective phase II trials investigated the effect of i.v. loading-dose ibandronate on metastatic bone pain in 45 patients with hormone-refractory prostate cancer and 55 patients with metastatic urologic cancer [14][15][16]. In both studies, patients with severe metastatic bone pain were treated with 6 mg i.v.…”

Section: Renal Safety Of Loading-dose Ibandronate For Metastatic Bonementioning

confidence: 99%

“…ibandronate in patients with existing renal impairment. The renal safety of ibandronate has been assessed in three clinical studies, including two in multiple myeloma patients [18,19] and one in urologic cancer patients [15,20].…”

Section: Renal Safety Of Ibandronate In Patients With Existing Renal mentioning

confidence: 99%

Renal Safety of Ibandronate

Jackson

2005

The Oncologist

View full text Add to dashboard Cite

897 High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer

Cited by 43 publications

References 0 publications

Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data

Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data

Preclinical Perspectives on Bisphosphonate Renal Safety

Renal Safety of Ibandronate

Contact Info

Product

Resources

About